Q2 EPS Estimate for Nektar Therapeutics Reduced by Analyst

Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Research analysts at B. Riley lowered their Q2 2025 earnings per share estimates for shares of Nektar Therapeutics in a note issued to investors on Monday, July 7th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will earn ($3.43) per share for the quarter, down from their previous estimate of ($2.55). B. Riley currently has a "Buy" rating and a $85.00 price objective on the stock. The consensus estimate for Nektar Therapeutics' current full-year earnings is ($0.72) per share. B. Riley also issued estimates for Nektar Therapeutics' Q3 2025 earnings at ($2.89) EPS, Q4 2025 earnings at ($3.06) EPS, FY2025 earnings at ($11.11) EPS, FY2026 earnings at ($11.61) EPS, FY2027 earnings at ($14.17) EPS, FY2028 earnings at ($12.89) EPS and FY2029 earnings at ($11.64) EPS.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($3.30) earnings per share for the quarter, missing the consensus estimate of ($2.70) by ($0.60). The firm had revenue of $10.46 million during the quarter, compared to analysts' expectations of $15.61 million. Nektar Therapeutics had a negative return on equity of 329.54% and a negative net margin of 152.49%. During the same quarter in the prior year, the company posted ($2.70) earnings per share.

NKTR has been the topic of several other research reports. Jefferies Financial Group upgraded Nektar Therapeutics from a "hold" rating to a "buy" rating and upped their price objective for the stock from $15.00 to $30.00 in a research report on Friday, April 11th. William Blair reaffirmed a "market perform" rating on shares of Nektar Therapeutics in a research note on Monday, May 12th. Oppenheimer upgraded Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $90.00 target price for the company in a report on Friday, March 14th. HC Wainwright raised their target price on Nektar Therapeutics to $120.00 and gave the company a "buy" rating in a report on Tuesday, June 24th. Finally, BTIG Research raised their target price on Nektar Therapeutics from $60.00 to $100.00 and gave the company a "buy" rating in a report on Tuesday, June 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Nektar Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $88.33.

Nektar Therapeutics Stock Performance

Shares of NKTR stock opened at $23.36 on Thursday. The stock's 50-day simple moving average is $13.67 and its 200-day simple moving average is $12.75. The firm has a market capitalization of $289.90 million, a PE ratio of -2.43 and a beta of 0.94. Nektar Therapeutics has a fifty-two week low of $6.48 and a fifty-two week high of $37.38.

Institutional Investors Weigh In On Nektar Therapeutics

Several large investors have recently modified their holdings of NKTR. Two Sigma Securities LLC raised its stake in shares of Nektar Therapeutics by 56.3% during the fourth quarter. Two Sigma Securities LLC now owns 27,654 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 9,958 shares during the last quarter. Harvest Investment Services LLC purchased a new stake in shares of Nektar Therapeutics during the fourth quarter worth approximately $27,000. US Asset Management LLC purchased a new stake in shares of Nektar Therapeutics during the fourth quarter worth approximately $31,000. Algert Global LLC purchased a new position in Nektar Therapeutics in the first quarter worth $33,000. Finally, US Bancorp DE raised its position in Nektar Therapeutics by 257.8% in the first quarter. US Bancorp DE now owns 50,085 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 36,085 shares in the last quarter. Hedge funds and other institutional investors own 75.88% of the company's stock.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.